GreenSignal Bio Pharma Ltd IPO Message Board (Page 17)

@septal ji.... sir @ cmp whether one can buy quess corp or advanced enzymes? Pls guide

Septa sir at what price would you prefer both & sir can we buy blue dart or any other stock for 4-5 months with small investment . Please sir guide me for that . Thanks

blue dart parent company has issue so i would stay away....

Home IPO News What you need to know about GreenSignal Bio Pharma IPO
IPO NEWSUPCOMING IPOS
What you need to know about GreenSignal Bio Pharma IPO
By Krishna Bagra - November 4, 2016 617 0
gsbpl-ipoWhen GreenSignal Bio Pharma IPO (GSBPL IPO) opens next week, it will be closely watched as the pharma company has no brand recall value in India. The timing of the IPO is intriguing as the markets are facing very high volatility on account of elections in the US and the possibility of Donald Trump becoming the next president. Here are the main points to be considered about the company and the IPO:

IPO details: GreenSignal Bio Pharma IPO will involve sale of 14,579,560 shares through an offer for sale (OFS). The shares will be sold in the price band of INR76 – 80 per share between 9 and 11 November.


History: The Chennai-based company was incorporated in November 2005. Promoted by P Murali, the company is engaged in the production of pharmaceutical vaccines. Commercial production started in the year 2009. As a result, the company has limited operating history.

Read Also: Greensignal Bio Pharma and Endurance Technologies added to India’s IPO pipeline

Two products: GreenSignal Bio Pharma is heavily dependent on two products – BCG Vaccine and BCG – ONCO for Immunotherapy. The latter is used in the treatment of urinary bladder cancer. BCG Vaccine is the major contributor to the company’s revenues and contributed 82.7% of its revenues in FY2016.

Order from UNICEF: The company has entered into a three year long term agreement with UNICEF to supply BCG Vaccines. The company received WHO – Pre-qualification in November 2015 which has made GreenSignal Bio Pharma one of the four companies globally to supply the BCG vaccine to UNICEF. Under the agreement, the company plans to supply 28 lakh (2.8 million) vials to UNICEF during 2016-2018 at prices between USD1.36 and USD1.8 per vial.



Order from Government of India: The company’s order book also includes the Ministry of Health which will purchase 25 lakh vials every year in FY2017 and FY2018 at the rate of INR36.75 per vial and INR39.5 per vial respectively. The Government of India accounted for 46.67% of its revenues for the quarter ended 30 June 2016.

Financial performance: GreenSignal Bio Pharma has witnessed uneven revenues in the last four years. Its revenues increased from INR11.26 crore in FY2012 to INR20.49 crore in FY2016 but the growth has been erratic as top line declined to just INR3.52 crore in FY2013. Similarly, profitability has also been elusive for the company. While GreenSignal Bio Pharma has been profitable in terms of operating profits, FY2016 was the only year of net profits in the last five financial years.



International operations: GreenSignal Bio Pharma’s international operations accounted for 46.2% of its annual revenues in FY2016. This high dependence on international markets is largely due to UNICEF supply deal.

Valuations: As the company was not profitable in the previous years, it is only FY2016 which matters in terms of profitability. In FY2016, its diluted earnings per share (EPS) stood at INR1.45 which means GSBPL IPO is valuing the company at a PE ratio55
MORE NEWS
Greensignal Bio Pharma Logo
What you need to know about GreenSignal Bio Pharma I

What is kostak rate in ahmedabad for green signal bio pharma ltd???

What you need to know about GreenSignal Bio Pharma IPO

initial view::::::

EPS

2016::::1.45
2017(1st quart) ::::0.76

So,Company asking PE between
26 to 55( @ upper price band 80)...with...
avg PE of 40....


.very small issue.
25x or more Rii possible

initial view::::::

EPS

2016::::1.45
2017(1st quart) ::::0.76

So,Company asking PE between
26 to 55( @ upper price band 80)...with...
avg PE of 40....


.very small issue.
25x or more Rii possible

Don''t know why but " they always come up with ipo as soon as balance sheet looks good " or "do some dressin so that financial looks promising,"

@Eagleye/@Septa Sir....please suggest subscribe or avoid????

IS THERE ANY GOVERNMENT THAT STOP FOOD PRICE RISE IN INDIA ?

Gsbpl last gmp......??????

WHAT IS EPS OF GREEN IPO TILL SEP OR JUNE 2016 FRM SEP 2015 ?

It''s very good to understand the development in the scientific community especially with those concerning the global diseases and the methods to eradicate them. One such step taken forward by this Company is the BCG vaccine and their ties with WHO and UNICEF.
It is also important to note that this vaccine is topping the list of solutions to Type1 Diabetes in the recent research. GSBF is moving ahead with no turning back !

in Green Signal Bio Pharma what is Retail Quota ?

Generic drug-maker Laurus Labs may launch Rs 1k cr IPO end-Nov


Moneycontrol Bureau

Generic drug-maker Laurus Labs is considering going public through an initial offer of Rs 1,000 crore, reports an article in the Mint today .
Laurus Labs makes active pharmaceutical ingredients (APIs) for select, high-growth therapeutic areas of antiretrovirals and Hepatitis C and those used in oncology and other therapeutic areas. Aspen Pharmacare, Aurobindo Pharma, Cipla, Mylan Laboratories, Natco Pharma and Strides Shasun are among the major customers.

Current investors Warburg Pincus Llc, with roughly 30.41 percent holding and Eight Roads Ventures with around 18.7 percent plan to offload their stakes in Laurus totalling Rs 700 crore. The balance Rs 300 crore will be raised through fresh share issue.

Hyberabad-based Laurus is currently conducting roadshows across various geographies and hopes to launch the IPO by end of November as verdict of the US Presidential elections is out and the market settles down.

Funds raised through the IPO will likely be utilised for debt repayment and other corporate expenditure.

It must be noted that this year so far, 24 companies have raised Rs.24,941 crore through the IPO route and investors have shown keen interest in the healthcare and pharmaceutical sectors.

Are you applying in agro phos

GreenSignal Bio Pharma fixes price band of Rs 76-80 for IPO

GreenSignal Bio Pharma fixes price band of Rs 76-80 for IPO
Vaccine manufacturing firm GreenSignal Bio Pharma has fixed the price band at Rs 76-80 per equity for its initial public offer (IPO) through which it plans to raise around Rs 112 crore.
The company is entering the capital market with its initial public offering of 1,45,79,560 equity shares of face value of Rs 10 each through an offer for sale by promoter selling shareholders P Sundaraparipooranan and P Murali, promoter''s group selling shareholder Mallika Murali and public selling shareholders R Srinivasan and Avon Cycles Ltd.

The 100 percent book building issue will open on November 9 and closes on November 11.

The equity shares are proposed to be listed on BSE and NSE.

The firm is engaged in manufacturing of BCG vaccine, given for protection against tuberculosis, mainly severe forms of childhood tuberculosis.

The global demand for BCG vaccines is estimated at approximately 280 million doses annually, with the highest requirement coming from India. The total shortfall for BCG vaccination is estimated at nearly 30 million doses annually, GSBPL Managing Director P Murali told reporters here.

GSBPL is one of the four companies worldwide who have been WHO-prequalified to supply the BCG vaccine to UNICEF.

At present the company produces two products namely BCG vaccine for immunisation against Tuberculosis and BCG-ONCO for Immunotherapy (Freeze Dried) BP for the treatment of urinary bladder Carcinoma.

The company''s major domestic client is Ministry of Health & Family Welfare and overseas client is UNICEF.

The company has a firm order of 84 lakhs vials to be executed in the next two years. GSBPL also exports products to 17 countries either directly through UNICEF or indirectly, through supply, distribution and other arrangements, Murali said.

Did some Research on Unicef web found Unicef is paying .075 cents 2017 and 9 cents in per dose and will take 8.4 million vials( 20 does per vial) from Greensignal which will give it top line just from Unicef 47 Crs at 25%NP margin will give it a 12 Cr NP just from Unicef deal WHICH IS AROUND 50% OF TOTAL SALES

SO IMO IT IS SCREAMING BUY NO MORE ANALYSIS JUST APPLY AND PRAY U GET

Source: http://www.unicef.org/supply/files/BCG.pdf
http://www.moneycontrol.com/news/ipo-news/greensignal-bio-pharma-fixes-price-bandrs-76-80-for-ipo_7891941.html

_/\_

Besides septa sir,whatever us election mandate & to some extent health of some European banks,what shall be indian market in context of 6-8 month..

Karan that is only option given the size of the issue if it list below 100 then i will certainly buy big. In total we have close to 40 different vaccination so lot of potential GSBP has only 2 vaccine with few more in pipeline according to it website.

GreenSignal Bio Pharma Ltd IPO Ma Invest Karha Chaiya What Result

Hello everyone
Who is eagleeye?

GSBP IPO ME KYA KARNA CHAHEYE

Considering listing in T Group, circuit limits of 5 percent will be applicable.
Which should make it Risky to exit on the date of listing itself.

Soo investos applying for listing gains should only apply after considering GMP trend and interest by NII and Institutional Investors.

Rs 4 - 7 movement in the Stock will trigger its Circuits. (Considering opening price anywhere in between 80 - 130).

Retail Investors with Short Term Perspective must be cautious before appyling.